The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
PPARs: therapeutic targets for metabolic disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Self-citationThe adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro
Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S., Spiegelman, B. M., & Mortensen, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80211-7 · Cited by 2,079
Cited by
(1998) · PubMed · Cited by 2,737
Tyagi, S., Gupta, P., Saini, A., Kaushal, C., & Sharma, S. (2011) · Journal of Advanced Pharmaceutical Technology & Research · doi:10.4103/2231-4040.90879 · Cited by 1,017
Metabolic requirements for the maintenance of self-renewing stem cells
Ito, K., & Suda, T. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3772 · Cited by 1,014
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Self-citationFeige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance
Ito, K., Carracedo, A., Weiss, D., Arai, F., Ala, U., Avigan, D. E., Schafer, Z. T., Evans, R. M., Suda, T., Lee, C.-H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2882 · Cited by 729
Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance
Meex, R. C. R., & Watt, M. J. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.56 · Cited by 631
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
PPARs and molecular mechanisms of transrepression
Ricote, M., & Glass, C. K. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.013 · Cited by 570
Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms
Straus, D. S., & Glass, C. K. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.09.003 · Cited by 554
Insulin resistance and atherosclerosis
Semenkovich, C. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29024 · Cited by 481
Arachidonic Acid Metabolism and Kidney Inflammation
Wang, T., Fu, X., Chen, Q., Patra, J. K., Wang, D., Wang, Z., & Gai, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153683 · Cited by 430
Partial Agonists Activate PPARγ Using a Helix 12 Independent Mechanism
Bruning, J. B., Chalmers, M. J., Prasad, S., Busby, S. A., Kamenecka, T. M., He, Y., Nettles, K. W., & Griffin, P. R. (2007) · Structure · doi:10.1016/j.str.2007.07.014 · Cited by 389
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral Inflammation
Villapol, S. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0554-5 · Cited by 369
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Feige, J. N., Gelman, L., Rossi, D., Zoete, V., Métivier, R., Tudor, C., Anghel, S. I., Grosdidier, A., Lathion, C., Engelborghs, Y., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702724200 · Cited by 356
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Yoon, M. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.02.004 · Cited by 336
Powell, W. S., & Rokach, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.10.008 · Cited by 324
Hair Follicle Stem Cell-Specific PPARγ Deletion Causes Scarring Alopecia
Karnik, P., Tekeste, Z., McCormick, T. S., Gilliam, A. C., Price, V. H., Cooper, K. D., & Mirmirani, P. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.369 · Cited by 321
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Muise, E. S., Azzolina, B., Kuo, D. W., El-Sherbeini, M., Tan, Y., Yuan, X., Mu, J., Thompson, J. R., Berger, J. P., & Wong, K. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.044826 · Cited by 294
Self-citationModes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver
Rusyn, I., Peters, J. M., & Cunningham, M. L. (2006) · Critical Reviews in Toxicology · doi:10.1080/10408440600779065 · Cited by 301
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02081.x · Cited by 292
Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARγ pathway
Huang, C., Zhang, Y., Gong, Z., Sheng, X., Li, Z., Zhang, W., & Qin, Y. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.07.095 · Cited by 278
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases
Bordet, R., Ouk, T., Petrault, O., Gelé, P., Gautier, S., Laprais, M., Deplanque, D., Duriez, P., Staels, B., Fruchart, J. C., et al. (2006) · Biochemical Society Transactions · doi:10.1042/bst0341341 · Cited by 273
Chuang, C.-C., & McIntosh, M. K. (2011) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-072610-145149 · Cited by 270
Dewulf, E. M., Cani, P. D., Neyrinck, A. M., Possemiers, S., Holle, A. V., Muccioli, G. G., Deldicque, L., Bindels, L. B., Pachikian, B. D., Sohet, F. M., et al. (2011) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2010.05.009 · Cited by 269
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
Araújo, J. R., Tomas, J., Brenner, C., & Sansonetti, P. J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.05.019 · Cited by 261
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0019 · Cited by 256
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
Tenenbaum, A., Motro, M., & Fisman, E. Z. (2005) · Cardiovascular Diabetology · doi:10.1186/1475-2840-4-14 · Cited by 246
Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators
Pirat, C., Farce, A., Lebègue, N., Renault, N., Furman, C., Millet, R., Yous, S., Speca, S., Berthelot, P., Desreumaux, P., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm101360s · Cited by 198
Searcy, J. L., Phelps, J. T., Pancani, T., Kadish, I., Popovic, J., Anderson, K. L., Beckett, T. L., Murphy, M. P., Chen, K.-C., Blalock, E. M., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111661 · Cited by 154
Effects of Antidiabetic Drugs on Gut Microbiota Composition
Montandon, S., & Jornayvaz, F. (2017) · Genes · doi:10.3390/genes8100250 · Cited by 135
Perfluoroalkyl substances and risk of type II diabetes: A prospective nested case-control study
Donat-Vargas, C., Bergdahl, I. A., Tornevi, A., Wennberg, M., Sommar, J., Kiviranta, H., Koponen, J., Rolandsson, O., & Åkesson, A. (2019) · Environment International · doi:10.1016/j.envint.2018.12.026 · Cited by 88
The molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
Meta-analysis of primary target genes of peroxisome proliferator-activated receptors
Heinäniemi, M., Uski, J. O., Degenhardt, T., & Carlberg, C. (2007) · Genome Biology · doi:10.1186/gb-2007-8-7-r147 · Cited by 71
In-depth analysis of lupeol: delving into the diverse pharmacological profile
Dalimunthe, A., Carensia Gunawan, M., Dhiya Utari, Z., Dinata, M. R., Halim, P., Estherina S. Pakpahan, N., Sitohang, A. I., Sukarno, M. A., Yuandani, Harahap, Y., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1461478 · Cited by 50
Nuclear Receptors in Nonalcoholic Fatty Liver Disease
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, N. (2012) · Journal of Lipids · doi:10.1155/2012/139875 · Cited by 48
Effects of IL-15 on rat brown adipose tissue: Uncoupling proteins and PPARs
Almendro, V., Fuster, G., Busquets, S., Ametller, E., Figueras, M., Argilés, J. M., & López‐Soriano, F. J. (2008) · Obesity · doi:10.1038/oby.2007.47 · Cited by 49
Li, Z., Yu, Z., Gao, P., & Yin, D. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.134762 · Cited by 46
Tranidou, A., Dagklis, T., Tsakiridis, I., Siargkas, A., Apostolopoulou, A., Mamopoulos, A., Goulis, D. G., & Chourdakis, M. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01464-6 · Cited by 43
Reardon, A. J. F., Karathra, J., Ribbenstedt, A., Benskin, J. P., MacDonald, A. M., Kinniburgh, D. W., Hamilton, T. J., Fouad, K., & Martin, J. W. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00192 · Cited by 40
Metadata
- Authors
- Berger, J. P., Akiyama, T. E., & Meinke, P. T.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2005-05
- Volume
- 26
- Issue
- 5
- Pages
- 244-251
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2060678630
- Cited by
- 713
- References
- 88
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.